“The approval was further complimented by the successful renewal of EUGMP license for 8 other manufacturing lines for various dosage forms including beta-lactam, non-beta lactam, terminal sterilization, mastitis, powder beta-lactam, aerosol, pesticide, and solids in Turkey,” the company said in a regulatory filing.
In addition to EUGMP, manufacturing lines in Turkey also hold GMP certificates from Turkish, Saudi, Ethiopian and Sudanese authorities, the company said in a regulatory filing.
Shares of the pharmaceutical firm surged 8 per cent to Rs 288.60 on Thursday. The counter was available at Rs 284.60 at 10 am. BSE Sensex was trading 122.98 points, or 0.23 per cent, higher at 53,027.03 at the same time. The scrip settled at Rs 267.80 on Wednesday.
According to the company, it is the third-largest player in the Turkish ruminant market with over 120 product registrations and a consolidated market share of about 10 per cent, operating through its 100 per cent subsidiaries of Provet and Topkim.
